1. Cedar Realty (CDR) is an integrated real estate investment trust, which focuses on ownership, operation, development and redevelopment of supermarket-anchored shopping centers in mid-Atlantic and northeast coastal states.
The company currently ranks No. 1 when it comes to dividend yields among companies in the retail REITs industry. The stock trades below book value and WRT Realty recently reported a 7.6 stake in the company, citing that it "intends to consider appropriate methods of maximizing the value" of Cedar Realty's common stock.
The stock currently trades near $4.50, which is about 32% below its 52-week high of $6.58 and 25% below the highest sell side analyst's 52-week target of $6.
Valuation Metrics
| Market Cap | 306.08M |
| Enterprise Value | 1.12B |
| PEG Ratio | 6.60 |
| Price/Sales | 1.80 |
| Price/Book | 0.82 |
| Enterprise Value/Revenue | 7.04 |
| Enterprise Value/EBITDA | 12.70 |
Balance Sheet
| Total Cash | 11.64M |
| Total Cash Per Share | 0.18 |
| Total Debt | 759.49M |
| Total Debt/Equity | 133.40 |
| Current Ratio | 0.23 |
| Book Value Per Share | 5.23 |
2. Oshkosh Corporation (OSK) is a designer, manufacturer and marketer of a range of vehicles and vehicle bodies.
As I write, shares of Oshkosh have a forward P/E of 11.25%. Unfortunately, there's no dividend story here, but the company seems poised for growth and has recently received another order from the U.S. government worth $10.3M.
The stock currently trades near $22.75, which is about 43% below its 52-week high of $40.11 and 35% below the highest sell side analyst's 52-week target of $35.
Valuation Metrics
| Market Cap | 2.07B |
| Enterprise Value | 2.59B |
| Forward P/E | 11.25 |
| PEG Ratio | 4.67 |
| Price/Sales | 0.26 |
| Price/Book | 1.22 |
| Enterprise Value/Revenue | 0.34 |
| Enterprise Value/EBITDA | 3.99 |
Balance Sheet
| Total Cash | 428.50M |
| Total Cash Per Share | 4.69 |
| Total Debt | 1.06B |
| Total Debt/Equity | 66.53 |
| Current Ratio | 1.45 |
| Book Value Per Share | 17.48 |
3. Natus Medical Incorporated (BABY) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders and balance and mobility disorders.
No dividend to mention, but the stock currently trades right around its book value, is 87% institutionally owned and its debt to cash ratio looks good. It is coming off of a bad year and shows some promise for a 2012 rebound.
The stock currently trades near $22.75, which is about 43% below its 52-week high of $17.50 and 11% below the highest sell side analyst's 52-week target of $11.
Valuation Metrics
| Market Cap | 284.67M |
| Enterprise Value | 242.01M |
| Forward P/E | 16.05 |
| PEG Ratio | 0.90 |
| Price/Sales | 1.17 |
| Price/Book | 0.99 |
| Enterprise Value/Revenue | 1.04 |
| Enterprise Value/EBITDA | 8.81 |
Balance Sheet
| Total Cash | 30.78M |
| Total Cash Per Share | 1.07 |
| Total Debt | 1.35M |
| Total Debt/Equity | 0.49 |
| Current Ratio | 3.13 |
| Book Value Per Share | 9.55 |
4. Teva Pharmaceutical Industries Limited (TEVA) is a global pharmaceutical and drug company.
The company very recently announced that Shlomo Yanai, the president and CEO of the company, will be retiring in May and that the board of directors has tapped Dr. Jeremy Levin, a former executive at Bristol-Myers Squibb (BMY), to succeed him. Over the course of five years, Yanai has transformed the company from an $8B-a-year generics manufacturer to a roughly $20B-a-year, diversified and globalized big pharma company. It is coming of a relatively disappointing year, but pays a respectable dividend and has a levered free cash flow of $2.21B.
The stock currently trades near $42.50, which is about 25% below its 52-week high of $57.08 and 36% below the highest sell side analyst's 52 week target of $67.
Valuation Metrics
| Market Cap | 37.65B |
| Enterprise Value | 42.77B |
| Forward P/E | 7.58 |
| PEG Ratio | 0.86 |
| Price/Sales | 2.09 |
| Price/Book | 1.56 |
| Enterprise Value/Revenue | 2.51 |
| Enterprise Value/EBITDA | 8.43 |
Balance Sheet
| Total Cash | 1.12B |
| Total Cash Per Share | 1.27 |
| Total Debt | 8.18B |
| Total Debt/Equity | 35.66 |
| Current Ratio | 1.13 |
| Book Value Per Share | 25.83 |
5. QuinStreet, Inc. (QNST) is a company that is engaged in vertical marketing and media on the Internet. It operates in two segments: Direct Marketing Services and Direct Selling Services.
While short interest represents about 7% of its total outstanding shares, making it the seventh highest shorted stock in its market segment, and from its most recent filing, both earnings and revenue growth are down a bit from the same period last year, the possibility for things to turn around this year are very real, as Quinstreet recently partnered with Hanley Wood, LLC to launch ProConnect, a service that is designed to match residential contractors with potentially millions of homeowners on an annual basis.
The stock currently trades near $10, which is about 60% below its 52-week high of $24.91 and 58% below the highest sell side analyst's 52-week target of $24.
Valuation Metrics
| Market Cap | 469.26M |
| Enterprise Value | 404.43M |
| Forward P/E | 9.87 |
| PEG Ratio | 0.72 |
| Price/Sales | 1.11 |
| Price/Book | 1.22 |
| Enterprise Value/Revenue | 1.01 |
| Enterprise Value/EBITDA | 5.67 |
Balance Sheet
| Total Cash | 145.30M |
| Total Cash Per Share | 3.05 |
| Total Debt | 103.80M |
| Total Debt/Equity | 28.37 |
| Current Ratio | 2.97 |
| Book Value Per Share | 7.69 |
6. Spartan Stores, Inc. (SPTN) is a regional grocery distributor and grocery retailer that operates mainly in Michigan and Indiana. It operates in two business segments: Distribution and Retail.
The stock sports an impressive dividend yield (for its market segment) of 1.5%. In the food distributors industry, Spartan ranks among the highest in terms of free cash-flow per share, highest future earnings growth potential and highest gross margin.
The stock currently trades near $19, which is about 11% below its 52 week high of $21.37 and 17% below the highest sell side analyst's 52 week target of $23.
Valuation Metrics
| Market Cap | 434.42M |
| Enterprise Value | 539.47M |
| Forward P/E | 12.97 |
| PEG Ratio | 1.32 |
| Price/Sales | 0.16 |
| Price/Book | 1.32 |
| Enterprise Value/Revenue | 0.21 |
| Enterprise Value/EBITDA | 5.32 |
Balance Sheet
| Total Cash | 62.08M |
| Total Cash Per Share | 2.72 |
| Total Debt | 178.56M |
| Total Debt/Equity | 55.55 |
| Current Ratio | 1.38 |
| Book Value Per Share | 14.06 |
All of the above listed names performed well on the first trading day of the year, but I suspect there will be better buying opportunities in the days to come. I would consider them all potentially good-to-great short term plays, as well as longer-term investments.
